Brought to you by 
Clarient sells up to $50mm in preferred shares
14 Apr 2009
Executive Summary
Cancer diagnostics company Clarient has sold 3.8mm Series A preferred shares to Oak Investment Partners for gross proceeds of $29.1mm. Each share is convertible into four common shares at any time and after one year will automatically convert if the company's stock trades over $4.75 for 20 consecutive days in a 30-day trading period. After four years the shares may be redeemed for $7.60 apiece.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
- Pharmaceuticals
-
In Vitro Diagnostics
- Cytology
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Financing
- Other
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com